

the Sorvall catalog. The capability of accurately measuring the setting of the knife-angle is pertinent because the thickness of the section is varied by varying the angle at which the knife enters the specimen.

For the foregoing reasons, we find that the Sorvall Model MT-2 ultramicrotome is not of equivalent scientific value to the foreign article, for the purposes for which such article is intended to be used.

The Department of Commerce knows of no other instrument or apparatus of equivalent scientific value to the foreign article, for the purposes for which such article is intended to be used, which is being manufactured in the United States.

CHARLEY M. DENTON,  
Assistant Administrator for Industry Operations, Business and Defense Services Administration.

[F.R. Doc. 68-13201; Filed, Oct. 30, 1968; 8:47 a.m.]

## DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

### Food and Drug Administration CHEMAGRO CORP.

#### Use of Filing of Petition Regarding Pesticide Chemicals

Pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (sec. 408(d)(1), 68 Stat. 512; 21 U.S.C. 346a(d)(1)), notice is given that a petition (PP 9F0762) has been filed by Chemagro Corp., Post Office Box 4913, Hawthorn Road, Kansas City, Mo. 64120, proposing that § 120.154 O,O-Dimethyl S-[4-oxo-1,2,3-benzotriazin-3(4H)-ylmethyl] phosphorodithioate; tolerances for residues (21 CFR 120.154) be amended to permit postharvest application of the subject insecticide in the production of tomatoes (currently, only preharvest application is permitted). No change is proposed in the tolerance level of 2 parts per million.

The analytical method proposed in the petition for determining residues of the insecticide is a colorimetric procedure based on the method of W. R. Meagher et al. published in the "Journal of Agricultural and Food Chemistry," 8:282 (1960).

Dated: October 23, 1968.

J. K. KIRK,  
Associate Commissioner  
for Compliance.

[F.R. Doc. 68-13235; Filed, Oct. 30, 1968; 8:50 a.m.]

### PHENFORMIN HYDROCHLORIDE

#### Drugs for Human Use—Drug Efficacy Study Implementation

The Food and Drug Administration has received and evaluated reports from the

National Academy of Sciences—National Research Council, Drug Efficacy Study Group, on the following preparations: DBI (phenformin hydrochloride, 25-milligram tablets) and DBI-TD (phenformin hydrochloride, 50-milligram timed disintegration capsules), marketed by U.S. Vitamin and Pharmaceutical Corp., 800 Second Avenue, New York, N.Y. 10017 (NDA Nos. 11-624 and 12-752).

The Food and Drug Administration concurs in the evaluation of the Academy that phenformin hydrochloride is an effective hypoglycemic agent when used in selected cases of diabetes mellitus and that labeling revisions are needed to narrow the conditions under which the drug is recommended for use.

An approved new-drug application pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act is required for marketing these articles.

The above-named applicant is requested to submit, within 60 days from the date of publication of this announcement in the FEDERAL REGISTER, supplements to its new-drug applications to provide for labeling revisions. Those parts of the labeling indicated below should be substantially as follows:

#### ACTION

The precise mode of action of phenformin is unknown; however, it does block aerobic glycolysis, does not stimulate insulin production, and may actually decrease insulin secretion.

#### INDICATIONS

Stable adult diabetes mellitus: Phenformin may be used alone or in combination with sulfonylureas. Sulfonylurea failures, primary and secondary: Phenformin may give satisfactory control.

Adjunct to insulin therapy of unstable diabetes mellitus adult and juvenile: Phenformin added to the insulin regimen may be of value in improving control.

#### CONTRAINDICATIONS

Diabetes mellitus that can be regulated by diet alone.

Juvenile diabetes mellitus that is uncomplicated and well regulated on insulin.

Acute complications of diabetes mellitus such as metabolic acidosis, coma, infection, gangrene, or during or immediately following surgery, where insulin is indispensable.

Severe hepatic disease.  
Renal disease with uremia.  
Cardiovascular collapse (shock).

After disease states associated with hypoxemia.

#### WARNINGS

USE IN PREGNANCY: The use of phenformin in any form is to be avoided in pregnancy. Adequate data on the effects on the fetus are not available at the present time, and use in pregnancy can be considered in the experimental stage.

#### PRECAUTIONS

DO NOT GIVE INSULIN WITHOUT FIRST CHECKING BLOOD AND URINE SUGAR DETERMINATIONS

1. Starvation ketosis: This must be differentiated from "insulin lack" ketosis and is characterized by ketonuria in spite of relatively normal blood sugar with little or no urinary sugar. This may result from excess phenformin HCl therapy, excessive insulin, or insufficient carbohydrate intake. Appropriate meas-

ures to supply carbohydrates or lower insulin or phenformin dosage result in alleviation of this state.

2. Lactic acidosis: Questions have arisen regarding the possible contribution of phenformin to the appearance of lactic acidosis in patients with renal disease and azotemia, as well as cardiovascular collapse (hypotensive state or hypoxemia) of any cause. In view of this it is recommended that phenformin HCl not be used in the presence of azotemia and in any clinical situation that predisposes to sustained hypotension that could lead to lactic acidosis.

Appropriate diagnostic measures should be taken in the diabetic patient who has been stabilized on phenformin hydrochloride or phenformin hydrochloride with insulin, and has subsequently become unstable, so that metabolic acidosis (which must be differentiated from ketosis of the diabetic type) may be properly diagnosed and treated. These include periodic determinations of ketones in blood and urine, electrolytes, pH, and lactate and pyruvate ratios. Either of these forms of acidosis necessitates the withdrawal of phenformin HCl and the use of insulin and other corrective measures.

3. Hypoglycemia: During the dosage adjustment period, hypoglycemic reactions may occur. Phenformin HCl and insulin dosages should be readjusted to conform with metabolic requirements.

#### ADVERSE REACTIONS

Principal side effects are related to the gastrointestinal tract, of which a warning signal is an unpleasant metallic taste. Anorexia, nausea, and, less frequently, vomiting and diarrhea are seen. At the first sign of gastrointestinal upset the dose of phenformin HCl should be reduced and, in case of vomiting, should be immediately withdrawn.

#### DOSAGE AND ADMINISTRATION

Oral therapy must be individualized, and low doses should be used initially with gradual adjustment of higher levels if needed. Phenformin HCl 25-milligram tablets should be administered orally with meals one to four times a day according to the patient's needs. Effective dosages for most diabetic patients may range from 50 to 150 milligrams daily. Some patients may respond to 25 milligrams daily while a few may require and tolerate dosages as high as 300 milligrams per day.

When timed-disintegration phenformin is used, one 50-milligram tablet with breakfast may be effective, or a second dose with the evening meal.

When phenformin HCl is administered to patients receiving insulin, dosage is adjusted in an individual pattern. Usually in patients receiving more than 30 units of insulin per day, the reduction of insulin is not more than 25 percent of the total daily dose. In stable, ketosis resistant, adult diabetes, insulin may be totally withdrawn (if less than 20-30 units) and the patient carefully observed for his clinical response.

The holder of the new-drug applications for these drugs has been mailed a

copy of the NAS-NRC reports along with a copy of the labeling conditions contained in this announcement. Any manufacturer, packer, or distributor of a drug of similar composition and labeling to the drugs listed in this announcement or any other interested person may obtain a copy of the NAS-NRC report by a request to the office named below.

Communications forwarded in response to this announcement should be directed to the attention of the following appropriate office and addressed to the Food and Drug Administration, 200 C Street SW., Washington, D.C. 20204:

Requests for NAS-NRC report: Press Relations Office (CE-300).

Supplements: Office of Marketed Drugs, tation, Bureau of Medicine (MD-16).

Comments on this announcement: Special Assistant for Drug Efficacy Study Implementation, Bureau of Medicine (MD-16).

This statement is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: October 23, 1968.

HERBERT L. LEY, Jr.,  
Commissioner of Food and Drugs.

[F.R. Doc. 68-13236; Filed, Oct. 30, 1968;  
8:51 a.m.]

## BUREAU OF THE BUDGET

### OAHE DAM AND RESERVOIR

#### Order Transferring Certain Lands From Department of Agriculture to Department of the Army

Whereas the hereinafter-described lands administered by the Secretary of Agriculture for conservation purposes under provisions of Title III of the Bankhead-Jones Farm Tenant Act are located adjacent to the Oahe Dam and Reservoir Project, S. Dak.; and

Whereas it appears that transfer of jurisdiction over such lands from the Secretary of Agriculture to the Secretary of the Army for administration pursuant to Title III would be in the public interest and in furtherance of the purposes thereof:

Now, therefore, by virtue of the authority vested in the President of the United States by the last sentence of section 32(c) of Title III of the Bankhead-Jones Farm Tenant Act of July 22, 1937 (50 Stat. 522, 526; 7 U.S.C. 1011 (c)), and delegated to the Director of the Bureau of the Budget by section 1(11) of Executive Order No. 11230 of June 28, 1965 (30 F.R. 8447), and upon the recommendation of the Secretary of Agriculture, it is ordered as follows:

Subject to valid existing rights, jurisdiction over the following described lands administered by the Secretary of Agriculture under the provisions of Title III of the said Bankhead-Jones Farm Tenant Act, together with waters or water rights, improvements, and struc-

tures administered or constructed in connection with the use and administration of said lands is hereby transferred to the Department of the Army for use in carrying on outdoor recreation, wild-life conservation, and other public programs in association with administration of the Oahe Dam and Reservoir Project, S. Dak.:

#### SOUTH DAKOTA-FORT SULLY PROJECT (SD-LU-5)

##### FIFTH PRINCIPAL MERIDIAN

T. 115 N., R. 81 W.,

Sec. 7, S $\frac{1}{2}$  of lot 7 except that portion lying within the E. 20 acres of said lot 7; lot 8; the SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$  (61 acres);

Sec. 17, NW $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; S $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; E $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; S $\frac{1}{2}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; S $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$  (90 acres);

Sec. 18, W $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SW $\frac{1}{4}$ NE $\frac{1}{4}$ ; W $\frac{1}{2}$ W $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ ; lot 1; W $\frac{1}{2}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; SE $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; NE $\frac{1}{4}$ SE $\frac{1}{4}$ ; NE $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ ; N $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$  (210.63 acres);

Sec. 20, NW $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; NE $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; S $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ ; E $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$ ; E $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$  (75 acres);

Sec. 21, W $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; W $\frac{1}{2}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$  (120 acres);

Sec. 26, SW $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$  (60 acres);

Sec. 27, lot 2; lot 5; lot 6; the S $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ S $\frac{1}{2}$ SW $\frac{1}{4}$ ; S $\frac{1}{2}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$  (268.47 acres);

Sec. 28, SW $\frac{1}{4}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ ; W $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SE $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SW $\frac{1}{4}$ NE $\frac{1}{4}$ ; W $\frac{1}{2}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ ; NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; E $\frac{1}{2}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; E $\frac{1}{2}$ W $\frac{1}{2}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ SE $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$  (300 acres);

Sec. 33, E $\frac{1}{2}$ NE $\frac{1}{4}$ ; E $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ NE $\frac{1}{4}$ ; E $\frac{1}{2}$ NE $\frac{1}{4}$ SE $\frac{1}{4}$  (130 acres);

Sec. 34, W $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; W $\frac{1}{2}$ W $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; W $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; W $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$  (35 acres);

T. 115 N., R. 82 W.,  
Sec. 1, S $\frac{1}{2}$  of lot 5 except the E. 15 acres thereof; the W $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; S $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ ; W $\frac{1}{2}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$  (160 acres);

Sec. 2, S. 20 acres of lot 1; lot 2; the E $\frac{1}{2}$  of lot 3; S $\frac{1}{2}$ NE $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; E $\frac{1}{2}$ E $\frac{1}{2}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; E $\frac{1}{2}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ ; S $\frac{1}{2}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$ ; NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$  (475.55 acres);

Sec. 3, S. 20 acres of lot 2; S $\frac{1}{2}$ NE $\frac{1}{4}$ ; NE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ SE $\frac{1}{4}$ ; NE $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ ; NE $\frac{1}{4}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$  (210 acres);

Sec. 11, NE $\frac{1}{4}$ ; NE $\frac{1}{4}$ NW $\frac{1}{4}$ ; NE $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ ; S $\frac{1}{2}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ S $\frac{1}{2}$ NW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ ; N $\frac{1}{2}$ N $\frac{1}{2}$ SE $\frac{1}{4}$  (330 acres);

Sec. 12, W $\frac{1}{2}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SE $\frac{1}{4}$ NW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SW $\frac{1}{4}$ NE $\frac{1}{4}$ ; SW $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$ ; NW $\frac{1}{4}$ ; NE $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ NW $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; N $\frac{1}{2}$ SE $\frac{1}{4}$ ; N $\frac{1}{2}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$ ; SE $\frac{1}{4}$ SE $\frac{1}{4}$  (490 acres).

T. 116 N., R. 82 W.,  
Sec. 35, SE $\frac{1}{4}$ SE $\frac{1}{4}$ SW $\frac{1}{4}$ ; SW $\frac{1}{4}$ SW $\frac{1}{4}$ SE $\frac{1}{4}$  (20 acres).

Acreage: 3,035.55 acres more or less.

Dated: October 24, 1968.

PHILLIP S. HUGHES,  
Acting Director,  
Bureau of the Budget.

[F.R. Doc. 68-13251; Filed, Oct. 30, 1968;  
8:52 a.m.]

## DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration  
INTERNATIONAL FIELD OFFICE  
JOHN F. KENNEDY INTERNATIONAL AIRPORT, JAMAICA, N.Y.

### Notice of Relocation

Notice is hereby given that on October 3, 1968, the International Field Office at John F. Kennedy International Airport, Jamaica, N.Y., was relocated to 181 South Franklin Avenue, Valley Stream, N.Y. 11581. This information will be reflected in the FAA Organization Statement the next time it is reissued.

(Sec. 313(a), 72 Stat. 752; 49 U.S.C. 1354)

Issued in Washington, D.C., on October 23, 1968.

RAYMOND B. MALOY,  
Assistant Administrator,  
Europe, Africa, and Middle East.

[F.R. Doc. 68-13198; Filed, Oct. 30, 1968;  
8:47 a.m.]

## CIVIL AERONAUTICS BOARD

[Docket No. 20253]

### ONE-STOP TOURIST FARES OF TRANS-CARIBBEAN AIRWAYS, INC.

#### Notice of Postponement of Prehearing Conference

Pursuant to the request of Trans Caribbean Airways, Inc., to which request the other parties do not object, the prehearing conference in this proceeding, presently scheduled to be held on October 25, 1968, is hereby postponed to November 12, 1968. The conference will be held in Room 701, Universal Building, Washington, D.C., commencing at 10 a.m.

Trans Caribbean Airways, Inc., agreed that if its request is granted it would voluntarily defer the effective date of the fares under investigation herein beyond the statutory period by the equivalent amount of time represented by the postponement. The request is granted pursuant to that agreement and with the understanding that the effective date will be so deferred.

Requests of the parties for the production of information or evidence shall be in writing and shall be served not later than November 5, 1968.

[SEAL]

E. ROBERT SEAVER,  
Hearing Examiner.

[F.R. Doc. 68-13238; Filed, Oct. 30, 1968;  
8:51 a.m.]

### MOHAWK AIRLINES, INC.

#### Notice of Application for Amendment of Certificate of Public Convenience and Necessity

OCTOBER 28, 1968.

Notice is hereby given that the Civil Aeronautics Board on October 25, 1968,